May 26, 2026 a 02:46 am
TECH: Dividend Analysis - Bio-Techne Corporation
Bio-Techne Corporation, a prominent player in the biotech sector, demonstrates a consistent dividend profile with a history of stable payouts. Despite modest dividend growth, their strategic financial management and substantial market capitalization underpin a solid foundation for income-seeking investors. Their diverse financial metrics suggest a stable and conservative approach to shareholder returns.
📊 Overview
Bio-Techne Corporation is positioned in the dynamic biotech sector, accentuated by a current dividend yield of 0.72%. With a dividend history spanning 19 years without any recent cuts or suspensions, the company exhibits robust dividend reliability.
| Metric | Value |
|---|---|
| Sector | Biotech |
| Dividend Yield | 0.72% |
| Current Dividend per Share | $0.32 |
| Dividend History | 19 years |
| Last Cut/Suspension | None |
🗣️ Dividend History
A strong indicator of financial health, Bio-Techne's long-standing dividend history is a testament to the company's steady cash flow generation and shareholder commitment. The consistency in payouts over the years underscores investor confidence and business sustainability.
| Year | Dividend per Share (USD) |
|---|---|
| 2026 | 0.16 |
| 2025 | 0.32 |
| 2024 | 0.32 |
| 2023 | 0.32 |
| 2022 | 0.32 |
📈 Dividend Growth
Analyzing dividend growth is vital for assessing a company’s future financial commitment. Bio-Techne shows no dividend growth over the short or long term. This flat growth can suggest a refocusing on reinvestment and internal growth or caution amid external market conditions.
| Time | Growth |
|---|---|
| 3 years | 0% |
| 5 years | 0% |
The average dividend growth is 0% over 5 years. This shows moderate but steady dividend growth.
📉 Payout Ratio
Payout ratios provide insights into the sustainability of dividend payments. Bio-Techne’s EPS-based payout ratio is 45.51%, suggesting a balanced approach between rewarding shareholders and retaining earnings. The FCF-based ratio is at 18.58%, indicating strong cash flow generation supports dividends without overburdening financial resources.
| Metric | Ratio |
|---|---|
| EPS-based | 45.51% |
| Free Cash Flow-based | 18.58% |
✅ Cashflow & Capital Efficiency
Examining cashflow metrics is crucial for understanding a company’s operational efficiency and financial health. Bio-Techne's capital efficiency metrics reflect effective cash management and reinvestment strategies to support long-term growth.
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Free Cash Flow Yield | 3.17% | 2.09% | 1.68% |
| Earnings Yield | 0.91% | 1.49% | 2.22% |
| CAPEX to Operating Cash Flow | 10.78% | 21.03% | 15.03% |
| Stock-based Compensation to Revenue | 3.35% | 3.28% | 3.45% |
| Free Cash Flow / Operating Cash Flow Ratio | 89.21% | 78.97% | 84.97% |
⚠️ Balance Sheet & Leverage Analysis
The balance sheet elements reflect on the company's financial leverage and liquidity. A stable debt-to-equity ratio and high interest coverage ensure financial agility and debt sustainability.
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Debt-to-Equity | 23.14% | 20.28% | 23.14% |
| Debt-to-Assets | 17.36% | 15.52% | 17.24% |
| Debt-to-Capital | 18.79% | 16.86% | 18.79% |
| Net Debt to EBITDA | 1.30 | 0.86 | 0.60 |
| Current Ratio | 3.46 | 3.87 | 4.84 |
| Quick Ratio | 2.38 | 2.75 | 3.50 |
| Financial Leverage | 1.33 | 1.31 | 1.34 |
🟢 Fundamental Strength & Profitability
Fundamentally, Bio-Techne's returns on equity and assets signify a competent use of resources, while profitable margins indicate efficient operational strategies.
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Return on Equity | 3.83% | 8.13% | 14.51% |
| Return on Assets | 2.87% | 6.21% | 10.81% |
| Margins: Net | 6.02% | 14.50% | 25.10% |
| Margins: EBIT | 8.77% | 17.38% | 30.78% |
| Margins: EBITDA | 17.78% | 27.02% | 40.21% |
| Margins: Gross | 64.80% | 66.41% | 67.72% |
| R&D to Revenue | 8.16% | 8.34% | 8.14% |
📉 Price Development
🔍 Dividend Scoring System
| Criterion | Score | Score Bar |
|---|---|---|
| Dividend yield | 3 | |
| Dividend stability | 5 | |
| Dividend growth | 2 | |
| Payout ratio | 4 | |
| Financial stability | 5 | |
| Dividend continuity | 5 | |
| Cashflow Coverage | 4 | |
| Balance Sheet Quality | 5 |
Total Score: 33/40
🗳️ Rating
Bio-Techne Corporation showcases a strong dividend stability and solid financial management, though with limited dividend growth. The company is well-positioned in the biotech sector, providing a reliable income source for conservative investors. However, monitoring for potential catalysts for dividend growth would be prudent.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years